PDGFC Antibodies

Structure of PDGFC

PDGF C is a type of protein that comes in pairs and has a weight of 30 kilodaltons (kDa). Its actual weight may differ slightly because of the way sugars attach to it and the unique variations, in amino acid sequences, among species.

PDGF C is a protein made up of two parts and sugars that consists of 126 building blocks called acids and has a structure, with a CUB part at the beginning and a PDGF homology part at the end. The CUB section keeps it stable in a form while the PDGF part connects with receptors like PDGFRA and PDGNRB to trigger pathways for communication within cells. In terms of its structure PDGF C has shapes and flat shapes that come together at the center. Joining together into pairs is crucial for its functions, in promoting cell growth, movement and repairing tissues.

Fig. 1 The domains of PDGFC.¹

Key structural properties of PDGFC:

• CUB domain (residues 50-160), encoded by exons 2-3.
• Growth factor domain (residues 231-345), forms cysteine knot.
• Signal peptide encoded by exon 1, cleaved at residues 22-23.
• Three N-linked glycosylation sites at positions 25, 55, 254.
• Hinge region (residues 161-230) connects domains.
• Latent form, activated by proteases like plasmin or tPA.

Functions of PDGFC

PDGFC primarily drives cell proliferation and survival, while also promoting angiogenesis, embryonic development, wound healing, fibrosis, and stem/progenitor cell regulation.

The activity of PDGFC is regulated by proteolytic activation, in contrast to other growth factors that may rely on receptor binding alone, indicating its latent form and requirement for processing to function.

Applications of PDGFC and PDGFC Antibody in Literature

1. Shi, Yin-Hao, et al. "Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer." Molecular Therapy 31.2 (2023): 503-516. https://doi.org/10.1016/j.ymthe.2022.11.004

The article shows that imatinib makes pancreatic cancer cells more responsive to gemcitabine through its action on the epigenetically activated PDGFC signaling pathway. The article explains how PDGFC signaling functions in pancreatic cancer while showing how imatinib treatment affects this pathway to enhance gemcitabine effectiveness.

2. Li, Xuri, et al. "Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors." The Journal of clinical investigation 115.1 (2005): 118-127. https://doi.org/10.1172/JCI19189

The article shows that PDGF-CC drives tissue revascularization through its ability to activate endothelial cells and their stem cells which makes it a promising therapeutic option for treating ischemic diseases.

3. Zwerner, Jeffrey P., and William A. May. "Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines." Oncogene 21.24 (2002): 3847-3854. https://doi.org/10.1038/sj.onc.1205486

This article demonstrates that dominant negative PDGF-C inhibits the growth of Ewing family tumor cell lines, highlighting its potential as a therapeutic strategy for these cancers.

4. Crawford, Yongping, et al. "PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment." Cancer cell 15.1 (2009): 21-34. https://doi.org/10.1016/j.ccr.2008.12.004

This article explains how PDGF-C plays a role in promoting the growth of blood vessels and tumors in cases where anti cancer treatment targeting VEGF's ineffective It highlights PDGF-C as a target, for potential therapeutic interventions, in such situations.

5. Yoon, Hyunho, et al. "Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis." Oncogene 40.11 (2021): 1957-1973. https://doi.org/10.1038/s41388-021-01685-w

The article shows that cancer-associated fibroblasts produce PDGFC which drives the growth and spread of gastrointestinal stromal tumors thus establishing PDGFC as a vital factor in tumor progression.

Creative Biolabs: PDGFC Antibodies for Research

Creative Biolabs is known for creating PDGF antibodies intended for research and medical use applications of the quality standards available, in the market right now. Our product range consists of monoclonal and polyclonal antibodies customized for ELISA tests as Western blot analysis and immunohistochemistry procedures along, with other diagnostic techniques.

• Custom PDGFC Antibody Development: Bespoke solutions to fulfill precise research needs.
• Large-Scale Manufacturing: High-volume antibody production for industrial partners.
• Expert Consultation: Professional support for optimizing protocols and solving issues.
• Custom Aliquoting: Practical aliquot sizes for extended storage and reliable results.

For further information on our PDGFC antibodies, custom services, or technical assistance, please reach out to us via info@creative-biolabs.com.